Skip to main content

EHR-Based Algorithm Does Not Cut Hospitalization in Kidney Dysfunction Triad

Medically reviewed by Carmen Pope, BPharm. Last updated on April 4, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, April 4, 2024 -- For patients with the triad of chronic kidney disease, type 2 diabetes, and hypertension, the use of an electronic health record-based algorithm and intervention does not result in reduced hospitalization at one year, according to a study published in the April 4 issue of the New England Journal of Medicine.

Miguel A. Vazquez, M.D., from the University of Texas Southwestern Medical Center in Dallas, and colleagues conducted an open-label, cluster-randomized trial involving 11,182 patients with the kidney-dysfunction triad treated at 141 primary care clinics to receive an intervention using a personalized algorithm (based on the electronic health record and practice facilitators to assist providers in delivery of guideline-based interventions) or to receive usual care. Seventy-one practices with 5,690 patients were assigned to the intervention group, and 70 practices with 5,492 patients were assigned to the usual-care group.

The researchers found that the hospitalization rate was 20.7 and 21.1 percent in the intervention and usual-care groups, respectively, at one year. The two groups had similar risks for emergency department visits, readmissions, cardiovascular events, dialysis, or death from any cause. The groups also had similar risks for adverse events, apart from acute kidney injury, which occurred in more patients in the intervention group (12.7 versus 11.3 percent).

"At one year, we did not find better disease control or reduced hospitalization with the intervention than with usual care," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Small but Important Differences Seen Between Rosuvastatin, Atorvastatin

WEDNESDAY, Oct. 30, 2024 -- There are small but important differences in risk for some clinical outcomes associated with rosuvastatin and atorvastatin, according to a study...

AI Can Help ID Patients With Diabetes at Highest Risk for Cardiomyopathy

WEDNESDAY, Oct. 30, 2024 -- Machine learning can help identify individuals with diabetes at high risk for diabetic cardiomyopathy (DbCM), according to a study published online...

ASN: Empagliflozin Offers Lasting Cardiorenal Benefit in CKD Patients

MONDAY, Oct. 28, 2024 -- Empagliflozin continues to offer cardiorenal benefits for up to 12 months after discontinuation among patients with chronic kidney disease at risk for...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.